Today's post10 Feb 2025 13:49
Physiomics plc
1,793 followers
2h
π° Our latest collaborative research with Merck KGaA, Darmstadt, Germany, now published in the British Journal of Cancer, explores optimising the use of DNA Damage Response (DDR) inhibitors, focusing on the complexities of dose and regimen selection for DDR combinations.
Our study highlights how PKPD modelling can guide both preclinical and clinical oncology decision-making, including optimising dosing strategies for diverse patient populations.
Check out the full paper here π
https://lnkd.in/eN-Y3Vzw
Nature Portfolio #OncologyResearch #DrugDevelopment #CombinationTherapies #PKPD #QSP #MIDD #ClinicalTrials #PharmaInnovation #MathematicalModelling #CancerTherapy